CGEN Stock Analysis: Buy, Sell, or Hold?
CGEN - Compugen Ltd
$2.30
-0.09 (-3.77%)
▼
5d:
-2.54%
30d:
+17.35%
90d:
-10.85%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Get Alerted When CGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CGEN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CGEN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CGEN is currently trading at $2.30, which is considered extended relative to its 30-day fair value range of $1.98 to $2.29.
Technical Outlook: Technically, CGEN is in a uptrend. Immediate support is located at $2.09, while resistance sits at $2.56. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: CGEN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.60 (+100.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CGEN is in a uptrend. Immediate support is located at $2.09, while resistance sits at $2.56. Short-term momentum is weak, with the stock down 3.8% recently.
Market Sentiment: CGEN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.60 (+100.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.98 -
$2.29
Company Quality Score
54/100
(HOLD)
Options IV Signal
54th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 54th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.8%)
- BULLISH: Trading 100.0% below Wall St target ($4.60)
Trading Range Analysis
30-Day Trading Range
$1.98 -
$2.29
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.42
(18.3%)
Support & Resistance Levels
Support Level
$2.09
Resistance Level
$2.56
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.30
Wall Street Target
$4.60
(+100.0%)
Revenue Growth (YoY)
-4.7%
Profit Margin
48.0%
Share & Embed Analysis
Last updated: July 14, 2026 5:09 AM ET
Data refreshes hourly during market hours. Next update: 6:09 AM
Data refreshes hourly during market hours. Next update: 6:09 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Eran Ophir
SELL
5000 shares
2026-04-14
Zurit Levine
SELL
3125 shares
2026-04-10
Zurit Levine
SELL
5375 shares
2026-04-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 56 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 45 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$277 | 51 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
